Lead Product(s): AMG510
Therapeutic Area: Oncology
Highest Development Status: Phase II Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 13, 2020
QIAGEN and Amgen to develop tissue-based therascreenÂ® test, paired with investigational treatment AMG 510, to identify patients whose cancers have KRAS G12C mutation.